ORYN 1001 / Oryn Therap - LARVOL DELTA

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=17; Completed; Sponsor: Oryn Therapeutics, LLC; Recruiting ➔ Completed

Clinical • Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Oryn Therapeutics, LLC; N=18 ➔ 0; Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

[VIRTUAL] Oryn Therapeutics LLC (BIO 2021) - "Oryn's lead candidate, ORTD-1, is in a Phase 1b study as a subcutaneous treatment for rheumatoid arthritis, and Oryn has an open IND for an intravenous formulation of ORTD-1. IND-enabling work is underway for development of a second Orynotide for cancer treatment. Oryn's strategy is to fund further development of its drug candidates and to seek strategic partners for selected product development programs."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Oryn Therapeutics, LLC; Trial completion date: Apr 2021 ➔ Sep 2021; Trial primary completion date: Mar 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Not yet recruiting; Sponsor: Oryn Therapeutics, LLC

Clinical • New P1 trial • Immunology • Rheumatoid Arthritis • Rheumatology • CRP

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Not yet recruiting; Sponsor: Oryn Therapeutics, LLC; Trial completion date: Oct 2020 ➔ Mar 2021; Initiation date: May 2020 ➔ Oct 2020; Trial primary completion date: Sep 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Oryn Therapeutics, LLC; Initiation date: Nov 2020 ➔ Feb 2021

Clinical • Trial initiation date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Recruiting; Sponsor: Oryn Therapeutics, LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs (clinicaltrials.gov) - P1b; N=16; Not yet recruiting; Sponsor: Oryn Therapeutics, LLC; Trial completion date: Jul 2020 ➔ Oct 2020; Initiation date: Feb 2020 ➔ May 2020; Trial primary completion date: Jun 2020 ➔ Sep 2020

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Rheumatoid Arthritis • Rheumatology • CRP

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia (clinicaltrials.gov) - P1/2; N=18; Recruiting; Sponsor: Oryn Therapeutics, LLC; Initiation date: Jan 2021 ➔ Apr 2021

Clinical • Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia (clinicaltrials.gov) - P1/2; N=18; Recruiting; Sponsor: Oryn Therapeutics, LLC

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases